We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $524M
1-Year Est. Return 164.42%
This Fund
S&P 500
This Quarter Est. Return
-9.26%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$321M
AUM Growth
-$44.2M
Cap. Flow
+$330K
Cap. Flow %
0.1%
Top 10 Hldgs %
50.52%
Holding
83
New
10
Increased
22
Reduced
13
Closed
8
Avg Time Held
10.1 quarters
Top 10 Avg Time Held
7.2 quarters
Top 20 Avg Time Held
8.5 quarters

Top Buys

Rank Stock Value
1
TSVT icon
2seventy bio
TSVT
+$6.24M
2
CYTK icon
Cytokinetics
CYTK
+$4.89M
3
AXGN icon
Axogen
AXGN
+$4.18M
4
TNDM icon
Tandem Diabetes Care
TNDM
+$3.04M
5
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$2.59M

Top Sells

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$24.1M
2
SAGE icon
Sage Therapeutics
SAGE
+$8.48M
3
DICE icon
DICE Therapeutics, Inc. Common Stock
DICE
+$5.93M
4
LYRA icon
LYRA THERAPEUTICS INC
LYRA
+$1.48M
5
RVMD icon
Revolution Medicines
RVMD
+$1.15M

Sector Composition

Rank Sector Weight
1 Healthcare 82.12%
2 Miscellaneous 17.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
XBI icon
1
State Street SPDR S&P Biotech ETF
XBI
$9.71B
$41.3M 12.83%
565,000
– –
2022 Q1
6 quarters
STXS icon
2
Stereotaxis
STXS
$106M
$21.6M 6.72%
13,680,554
– –
2013 Q2
41 quarters
CYTK icon
3
Cytokinetics
CYTK
$8.57B
$14.1M 4.39%
479,538
+146,804
+44% +$4.89M
2021 Q3
8 quarters
IDYA icon
4
IDEAYA Biosciences
IDYA
$3.31B
$13.5M 4.19%
499,820
+20,000
+4% +$507K
2020 Q3
12 quarters
RVMD icon
5
Revolution Medicines
RVMD
$40.4B
$13.1M 4.08%
473,394
-38,891
-8% -$1.15M
2020 Q4
11 quarters
ASND icon
6
Ascendis Pharma A/S
ASND
$14.7B
$12.8M 3.97%
136,212
+1,000
+0.7% +$93.6K
2021 Q4
7 quarters
IBB icon
7
iShares Biotechnology ETF
IBB
$10.2B
$12.5M 3.9%
102,500
– –
2016 Q4
27 quarters
BPMC icon
8
DELISTED
Blueprint Medicines
BPMC
$12.5M 3.9%
249,521
-2,000
-0.8% -$107K
2016 Q4
27 quarters
MRUS icon
9
DELISTED
Merus
MRUS
$11.4M 3.56%
484,870
+100,000
+26% +$2.43M
2021 Q1
10 quarters
XENE icon
10
Xenon Pharmaceuticals
XENE
$3.33B
$9.58M 2.98%
280,538
– –
2015 Q3
32 quarters
KRTX icon
11
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$8.94M 2.78%
52,873
+10,700
+25% +$2.01M
2020 Q1
14 quarters
NBIX icon
12
Neurocrine Biosciences
NBIX
$13.7B
$8.28M 2.58%
73,615
-1,000
-1% -$105K
2016 Q1
30 quarters
DAWN icon
13
DELISTED
Day One Biopharmaceuticals
DAWN
$7.2M 2.24%
586,463
+79,363
+16% +$1.04M
2023 Q2
1 quarter
SNDX icon
14
Syndax Pharmaceuticals
SNDX
$1.25B
$6.66M 2.07%
458,373
+7,500
+2% +$142K
2020 Q2
13 quarters
DXCM icon
15
DexCom
DXCM
$32.1B
$6.3M 1.96%
67,552
– –
2017 Q3
24 quarters
KALV icon
16
DELISTED
KalVista Pharmaceuticals
KALV
$5.83M 1.81%
605,532
-5,500
-0.9% -$56.2K
2021 Q1
10 quarters
TSVT icon
17
DELISTED
2seventy bio
TSVT
$5.67M 1.76%
1,447,465
+951,049
+192% +$6.24M
2023 Q2
1 quarter
ATRC icon
18
AtriCure
ATRC
$2.89B
$5.5M 1.71%
125,529
– –
2013 Q2
41 quarters
MORF icon
19
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$5.31M 1.65%
231,748
+25,000
+12% +$1.31M
2020 Q4
11 quarters
KURA icon
20
Kura Oncology
KURA
$874M
$5.02M 1.56%
550,784
+193,000
+54% +$1.96M
2017 Q3
24 quarters
AXGN icon
21
Axogen
AXGN
$2.12B
$4.68M 1.46%
935,894
+603,791
+182% +$4.18M
2021 Q4
7 quarters
BCRX icon
22
BioCryst Pharmaceuticals
BCRX
$2.06B
$4.62M 1.44%
652,000
+83,000
+15% +$596K
2022 Q4
3 quarters
TNDM icon
23
Tandem Diabetes Care
TNDM
$1.16B
$4.58M 1.43%
220,708
+110,708
+101% +$3.04M
2023 Q2
1 quarter
NRIX icon
24
Nurix Therapeutics
NRIX
$2.42B
$4.38M 1.36%
556,695
– –
2021 Q1
10 quarters
ALEC icon
25
Alector
ALEC
$209M
$4.08M 1.27%
628,938
-10,000
-2% -$64.7K
2021 Q3
8 quarters
1
2 3 4

Similar funds

4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
BB
Berkshire Bank Pittsfield, Massachusetts $524M AUM 21.97% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM
HW
Hedeker Wealth Lincolnshire, Illinois $524M AUM 36.83% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return
SDWIA
Schwarz Dygos Wheeler Investment Advisors Minneapolis, Minnesota $524M AUM 25.1% 1-Year Est. Return
SCA
Stieven Capital Advisors St. Louis, Missouri $524M AUM 29.72% 1-Year Est. Return
BHPW
Beverly Hills Private Wealth Beverly Hills, California $525M AUM 24.1% 1-Year Est. Return

DAFNA Capital Management's Q3 2023 Portfolio in Review

As of Q3 2023, DAFNA Capital Management held 83 positions worth $321M, down 12% from $366M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

DAFNA Capital Management's Q3 2023 filing shows 10 new, 22 increased, 13 reduced and 8 closed positions. Its largest new stake was Amylyx Pharmaceuticals: 122,547 shares worth $2.24M. The largest sale was IVERIC bio, Inc. Common Stock, an estimated $24.1M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 83% a quarter earlier, followed by Miscellaneous.

  • DAFNA Capital Management's largest Q3 2023 buy was Amylyx Pharmaceuticals: 122,547 shares worth $2.24M.
  • DAFNA Capital Management added most to 2seventy bio in Q3 2023, an estimated $6.24M increase.
  • DAFNA Capital Management's biggest Q3 2023 reduction was Revolution Medicines, cutting an estimated $1.15M.
  • DAFNA Capital Management fully exited IVERIC bio, Inc. Common Stock in Q3 2023, selling an estimated $24.1M.
  • DAFNA Capital Management's ten largest holdings make up 51% of its $321M portfolio in Q3 2023.
  • DAFNA Capital Management opened 10 new positions and closed 8 in Q3 2023.
  • DAFNA Capital Management's portfolio value fell 12% quarter-over-quarter to $321M.

Based on DAFNA Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.